Does Dr. Demina study stroke treatments?

Yes, Dr. Demina focuses on treatments for ischemic strokes, specifically evaluating the impacts of the medication Revelise.

What are the outcomes of using Revelise for stroke patients?

The research found that nearly half of stroke patients treated with Revelise had good outcomes at discharge, with improvement noted over the following 90 days.

Is Dr. Demina's work relevant for older stroke patients?

Yes, Dr. Demina's studies specifically include older patients, showing that Revelise is effective and beneficial for this group.

What is Revelise used for?

Revelise is used to treat ischemic strokes, helping to restore blood flow to the brain and reduce disabilities.

How many patients were involved in Dr. Demina's study?

The study involved 2,202 patients, providing a robust set of data on the treatment's effectiveness.

S A Demina

City Clinical Hospital No. 14, Yekaterinburg, Russia.

1 publication 2025 – 2025 ORCID

Russia Ischemic Stroke Fibrinolytic Agents Tissue Plasminogen Activator Thrombolytic Therapy

What does S A Demina research?

S A Demina studies how well the medication Revelise works for patients who have experienced ischemic strokes, a condition where blood flow to the brain is blocked. Their research involves analyzing patient outcomes after treatment, particularly examining how many individuals recover well and experience fewer disabilities in the weeks and months following a stroke. By studying a large group of patients, including older adults and those with additional health issues, Demina aims to provide insights into how effective this treatment is across different demographics.

Key findings

In a study of 2,202 patients, 49.9% had good outcomes at discharge after using Revelise for ischemic stroke treatment.
This percentage improved to 66.4% after 90 days post-treatment, indicating significant recovery over time.
The research confirms that Revelise helps reduce stroke-related disabilities, making it effective even in older patients and those with other health complications.

Frequently asked questions

Does Dr. Demina study stroke treatments?: Yes, Dr. Demina focuses on treatments for ischemic strokes, specifically evaluating the impacts of the medication Revelise.
What are the outcomes of using Revelise for stroke patients?: The research found that nearly half of stroke patients treated with Revelise had good outcomes at discharge, with improvement noted over the following 90 days.
Is Dr. Demina's work relevant for older stroke patients?: Yes, Dr. Demina's studies specifically include older patients, showing that Revelise is effective and beneficial for this group.
What is Revelise used for?: Revelise is used to treat ischemic strokes, helping to restore blood flow to the brain and reduce disabilities.
How many patients were involved in Dr. Demina's study?: The study involved 2,202 patients, providing a robust set of data on the treatment's effectiveness.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.